2025 Q3 -tulosraportti
Vain PDF
40 päivää sitten
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
70
Myynti
Määrä
6 461
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 70 | AVA | AVA | ||
| 100 | AVA | SSWM | ||
| 1 203 | SSWM | NON | ||
| 1 262 | NON | NON | ||
| 150 | NON | NON |
Ylin
15,28VWAP
Alin
14,22VaihtoMäärä
1,1 76 167
VWAP
Ylin
15,28Alin
14,22VaihtoMäärä
1,1 76 167
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 6 539 | 0 | +6 539 | 0 |
| Nordea Bank Abp | 2 317 | 359 | +1 958 | 0 |
| Svenska Handelsbanken AB | 3 000 | 1 950 | +1 050 | 0 |
| Carnegie Investment Bank AB | 73 | 119 | −46 | 0 |
| Danske Bank A/S | 150 | 261 | −111 | 0 |
| Nordnet Bank AB | 46 521 | 49 099 | −2 578 | 27 952 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 7 377 | 11 188 | −3 811 | 0 |
| Avanza Bank AB | 10 190 | 13 191 | −3 001 | 3 305 |
| Nordnet Bank AB | 46 521 | 49 099 | −2 578 | 27 952 |
| Danske Bank A/S | 150 | 261 | −111 | 0 |
| Carnegie Investment Bank AB | 73 | 119 | −46 | 0 |
| Svenska Handelsbanken AB | 3 000 | 1 950 | +1 050 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11. | |
| 2025 Q2 -tulosraportti | 21.8. | |
| 2025 Q1 -tulosraportti | 15.5. | |
| 2024 Q4 -tulosraportti | 28.2. | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Datan lähde: Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 t sitten · MuokattuHave others also noticed that Ventis Pharma has changed the URL for their Dental Division subpage? It is now called: https://ventispharma.com/dental-division/ (formerly https://ventispharma.com/ventis-pharma-dental-division, which is now inactive). It now indirectly states that Sedare can be pre-ordered, and refers to a new website - ventispharmadental.com - which is not yet active.: "Compliance Statement All Ventis Pharma compounded preparations are produced in FDA-registered 503B Outsourcing Facilities that comply with current Good Manufacturing Practices (cGMP). These products are made on a per-order basis for office use by licensed healthcare professionals. They are not intended for individual patient dispensing or direct-to-consumer promotion. For professional inquiries or order requests: Ventis Pharma Dental Division www.ventispharmadental.com" ...NOW it won't be long until that launch is official.. ;)
23 t sitten23 t sittenTämä julkaisu on poistettu.
·21 t sittenThe current price of approx 14 kr gives the company a value of around 250 mill kr. If Ventis and Cessatech share expenses and costs with a margin of 25% from sales in the USA, and if the share price is set at approx 12 x annual revenue, one can roughly calculate that the current price corresponds to an expected sale in the USA of 250 / (12 x 0.5 x 0.25) = 166 mill kr or around 27 mill USD per year. This is very far from the market potential that Ventis itself has estimated at over 500 mill USD. This does not include sales in the EU or the value of Cessatech’s other development program. So I would not say that future expectations are built into the current price. I would rather say that there is a degree of “it’s almost too good to be true” and “can they really pull it off” - skepticism built into the price. So I believe that the share price development will follow earnings in a reasonable symbiosis. Which is also preferable. But let's see - and please come soon with an announcement about the launch in the USA.
·16 t sittenWhat I'm saying we don't know are the sales figures and the growth in these (of course also the peak sales, but that should be able to become large enough). So, will they generate e.g. 2 mio. USD or 9 mio. USD in 2026? Will it be 6 mio. USD or 27 mio. USD in 2027? Or more or less... It's not that clear, and it means a great deal for the time horizon. It's crucial for me whether it's a good business in 3 years or in 8 years. Don't want to transfer more to Nordnet and can't buy shares on the small spotlight exchange at the bank, so I'll wait until I see the sales figures, there will probably be an opportunity later. It might be at a higher price, but then also with more clarity and therefore less risk. I'll buy your shares 1/3 of the way to the top, when someone here exits - if it goes the right way - and then take the last part of the journey 😉
·19.12.We have been at 15 before - I wonder if we'll go higher this time :-) 🚀🚀🚀
·1 päivä sittenThat sounds super good. Congratulations on that.- ·18.12.From a comment thread: SedareTM (CT-001) is mentioned on Ventis' website now, which typically happens shortly before launch. https://ventispharma.com/ventis-pharma-dental-division/ My guess is that a bunch of investors decided to buy a relatively large portion of shares without worrying if the price was 13 or 14.5 kr. The alternative, not getting bought in time and thus risking missing out on an expected upturn, was more concerning.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
40 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sitten · MuokattuHave others also noticed that Ventis Pharma has changed the URL for their Dental Division subpage? It is now called: https://ventispharma.com/dental-division/ (formerly https://ventispharma.com/ventis-pharma-dental-division, which is now inactive). It now indirectly states that Sedare can be pre-ordered, and refers to a new website - ventispharmadental.com - which is not yet active.: "Compliance Statement All Ventis Pharma compounded preparations are produced in FDA-registered 503B Outsourcing Facilities that comply with current Good Manufacturing Practices (cGMP). These products are made on a per-order basis for office use by licensed healthcare professionals. They are not intended for individual patient dispensing or direct-to-consumer promotion. For professional inquiries or order requests: Ventis Pharma Dental Division www.ventispharmadental.com" ...NOW it won't be long until that launch is official.. ;)
- 23 t sitten23 t sittenTämä julkaisu on poistettu.·21 t sittenThe current price of approx 14 kr gives the company a value of around 250 mill kr. If Ventis and Cessatech share expenses and costs with a margin of 25% from sales in the USA, and if the share price is set at approx 12 x annual revenue, one can roughly calculate that the current price corresponds to an expected sale in the USA of 250 / (12 x 0.5 x 0.25) = 166 mill kr or around 27 mill USD per year. This is very far from the market potential that Ventis itself has estimated at over 500 mill USD. This does not include sales in the EU or the value of Cessatech’s other development program. So I would not say that future expectations are built into the current price. I would rather say that there is a degree of “it’s almost too good to be true” and “can they really pull it off” - skepticism built into the price. So I believe that the share price development will follow earnings in a reasonable symbiosis. Which is also preferable. But let's see - and please come soon with an announcement about the launch in the USA.·16 t sittenWhat I'm saying we don't know are the sales figures and the growth in these (of course also the peak sales, but that should be able to become large enough). So, will they generate e.g. 2 mio. USD or 9 mio. USD in 2026? Will it be 6 mio. USD or 27 mio. USD in 2027? Or more or less... It's not that clear, and it means a great deal for the time horizon. It's crucial for me whether it's a good business in 3 years or in 8 years. Don't want to transfer more to Nordnet and can't buy shares on the small spotlight exchange at the bank, so I'll wait until I see the sales figures, there will probably be an opportunity later. It might be at a higher price, but then also with more clarity and therefore less risk. I'll buy your shares 1/3 of the way to the top, when someone here exits - if it goes the right way - and then take the last part of the journey 😉
- ·19.12.We have been at 15 before - I wonder if we'll go higher this time :-) 🚀🚀🚀·1 päivä sittenThat sounds super good. Congratulations on that.
- ·18.12.From a comment thread: SedareTM (CT-001) is mentioned on Ventis' website now, which typically happens shortly before launch. https://ventispharma.com/ventis-pharma-dental-division/ My guess is that a bunch of investors decided to buy a relatively large portion of shares without worrying if the price was 13 or 14.5 kr. The alternative, not getting bought in time and thus risking missing out on an expected upturn, was more concerning.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
70
Myynti
Määrä
6 461
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 70 | AVA | AVA | ||
| 100 | AVA | SSWM | ||
| 1 203 | SSWM | NON | ||
| 1 262 | NON | NON | ||
| 150 | NON | NON |
Ylin
15,28VWAP
Alin
14,22VaihtoMäärä
1,1 76 167
VWAP
Ylin
15,28Alin
14,22VaihtoMäärä
1,1 76 167
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 6 539 | 0 | +6 539 | 0 |
| Nordea Bank Abp | 2 317 | 359 | +1 958 | 0 |
| Svenska Handelsbanken AB | 3 000 | 1 950 | +1 050 | 0 |
| Carnegie Investment Bank AB | 73 | 119 | −46 | 0 |
| Danske Bank A/S | 150 | 261 | −111 | 0 |
| Nordnet Bank AB | 46 521 | 49 099 | −2 578 | 27 952 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 7 377 | 11 188 | −3 811 | 0 |
| Avanza Bank AB | 10 190 | 13 191 | −3 001 | 3 305 |
| Nordnet Bank AB | 46 521 | 49 099 | −2 578 | 27 952 |
| Danske Bank A/S | 150 | 261 | −111 | 0 |
| Carnegie Investment Bank AB | 73 | 119 | −46 | 0 |
| Svenska Handelsbanken AB | 3 000 | 1 950 | +1 050 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11. | |
| 2025 Q2 -tulosraportti | 21.8. | |
| 2025 Q1 -tulosraportti | 15.5. | |
| 2024 Q4 -tulosraportti | 28.2. | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Datan lähde: Quartr
2025 Q3 -tulosraportti
Vain PDF
40 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 13.11. | |
| 2025 Q2 -tulosraportti | 21.8. | |
| 2025 Q1 -tulosraportti | 15.5. | |
| 2024 Q4 -tulosraportti | 28.2. | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Datan lähde: Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sitten · MuokattuHave others also noticed that Ventis Pharma has changed the URL for their Dental Division subpage? It is now called: https://ventispharma.com/dental-division/ (formerly https://ventispharma.com/ventis-pharma-dental-division, which is now inactive). It now indirectly states that Sedare can be pre-ordered, and refers to a new website - ventispharmadental.com - which is not yet active.: "Compliance Statement All Ventis Pharma compounded preparations are produced in FDA-registered 503B Outsourcing Facilities that comply with current Good Manufacturing Practices (cGMP). These products are made on a per-order basis for office use by licensed healthcare professionals. They are not intended for individual patient dispensing or direct-to-consumer promotion. For professional inquiries or order requests: Ventis Pharma Dental Division www.ventispharmadental.com" ...NOW it won't be long until that launch is official.. ;)
- 23 t sitten23 t sittenTämä julkaisu on poistettu.·21 t sittenThe current price of approx 14 kr gives the company a value of around 250 mill kr. If Ventis and Cessatech share expenses and costs with a margin of 25% from sales in the USA, and if the share price is set at approx 12 x annual revenue, one can roughly calculate that the current price corresponds to an expected sale in the USA of 250 / (12 x 0.5 x 0.25) = 166 mill kr or around 27 mill USD per year. This is very far from the market potential that Ventis itself has estimated at over 500 mill USD. This does not include sales in the EU or the value of Cessatech’s other development program. So I would not say that future expectations are built into the current price. I would rather say that there is a degree of “it’s almost too good to be true” and “can they really pull it off” - skepticism built into the price. So I believe that the share price development will follow earnings in a reasonable symbiosis. Which is also preferable. But let's see - and please come soon with an announcement about the launch in the USA.·16 t sittenWhat I'm saying we don't know are the sales figures and the growth in these (of course also the peak sales, but that should be able to become large enough). So, will they generate e.g. 2 mio. USD or 9 mio. USD in 2026? Will it be 6 mio. USD or 27 mio. USD in 2027? Or more or less... It's not that clear, and it means a great deal for the time horizon. It's crucial for me whether it's a good business in 3 years or in 8 years. Don't want to transfer more to Nordnet and can't buy shares on the small spotlight exchange at the bank, so I'll wait until I see the sales figures, there will probably be an opportunity later. It might be at a higher price, but then also with more clarity and therefore less risk. I'll buy your shares 1/3 of the way to the top, when someone here exits - if it goes the right way - and then take the last part of the journey 😉
- ·19.12.We have been at 15 before - I wonder if we'll go higher this time :-) 🚀🚀🚀·1 päivä sittenThat sounds super good. Congratulations on that.
- ·18.12.From a comment thread: SedareTM (CT-001) is mentioned on Ventis' website now, which typically happens shortly before launch. https://ventispharma.com/ventis-pharma-dental-division/ My guess is that a bunch of investors decided to buy a relatively large portion of shares without worrying if the price was 13 or 14.5 kr. The alternative, not getting bought in time and thus risking missing out on an expected upturn, was more concerning.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
70
Myynti
Määrä
6 461
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 70 | AVA | AVA | ||
| 100 | AVA | SSWM | ||
| 1 203 | SSWM | NON | ||
| 1 262 | NON | NON | ||
| 150 | NON | NON |
Ylin
15,28VWAP
Alin
14,22VaihtoMäärä
1,1 76 167
VWAP
Ylin
15,28Alin
14,22VaihtoMäärä
1,1 76 167
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 6 539 | 0 | +6 539 | 0 |
| Nordea Bank Abp | 2 317 | 359 | +1 958 | 0 |
| Svenska Handelsbanken AB | 3 000 | 1 950 | +1 050 | 0 |
| Carnegie Investment Bank AB | 73 | 119 | −46 | 0 |
| Danske Bank A/S | 150 | 261 | −111 | 0 |
| Nordnet Bank AB | 46 521 | 49 099 | −2 578 | 27 952 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 7 377 | 11 188 | −3 811 | 0 |
| Avanza Bank AB | 10 190 | 13 191 | −3 001 | 3 305 |
| Nordnet Bank AB | 46 521 | 49 099 | −2 578 | 27 952 |
| Danske Bank A/S | 150 | 261 | −111 | 0 |
| Carnegie Investment Bank AB | 73 | 119 | −46 | 0 |
| Svenska Handelsbanken AB | 3 000 | 1 950 | +1 050 | 0 |